𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer

✍ Scribed by Athanassios Argiris; Kerstin M. Stenson; Bruce E. Brockstein; Bharat B. Mittal; Harold Pelzer; Merrill S. Kies; Prathima Jayaram; Louis Portugal; Barry L. Wenig; Fred R. Rosen; Daniel J. Haraf; Everett E. Vokes

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
189 KB
Volume
26
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Purpose.

The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck.

Methods.

We identified patients with N2–N3 head and neck cancers who were enrolled in three consecutive multicenter phase II studies of concurrent chemoradiotherapy utilizing 5‐fluorouracil and hydroxyurea on an alternate‐week schedule with radiotherapy twice daily plus either cisplatin (C‐FHX) or paclitaxel (T‐FHX). Patients with unknown primary tumors, nasopharyngeal or paranasal sinus primaries, nonsquamous histology, progression or death during therapy, or incomplete therapy were excluded.

Results.

A total of 131 patients were analyzed. Seventy‐nine percent had N2 stage. ND was performed in 92 patients (70%), either prior to enrollment (n = 31) or after chemoradiotherapy (n = 61). With a median follow‐up of 4.6 years, the 5‐year locoregional and neck progression‐free survival (PFS) rates were higher in patients with ND versus patients without ND: 88% versus 74% (p = .02) and 99% versus 82% (p = .0007). respectively; there was also a trend toward improved overall survival (OS) with ND, but PFS and distant PFS were comparable. In the subset of patients with N3 disease, ND was associated not only with better locoregional control but also with improved distant PFS. However, in patients with clinical complete response (n = 92), no significant differences in PFS (68% vs 75% at 5 years, p = .53) or any other survival parameters with or without ND were observed.

Conclusions.

ND improves neck control and is required for patients with clinically residual disease or N3 neck cancer but has no significant impact on the outcome of patients with N2 stage disease who are rendered clinically disease‐free with intensive concurrent chemoradiotherapy.© 2003 Wiley Periodicals, Inc. Head Neck 26: 447–455, 2004

📜 SIMILAR VOLUMES

Planned postradiotherapy neck dissection
Planned postradiotherapy neck dissection in patients with advanced head and neck cancer
✍ Timothy S. Boyd; Paul M. Harari; Scott P. Tannehill; Marta C. Voytovich; Gregory 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## Background: Metastatic neck nodes in patients with squamous cell carcinoma of the head and neck are most commonly managed by surgery, radiotherapy, or combined-modality therapy. for combined-modality cases, the sequencing of surgery and radiotherapy is generally guided by which modality is consi

Local control in advanced head and neck
Local control in advanced head and neck cancer by combined modalities of treatment
✍ Baby Jose; Yusuf Desmukh; Subhash C. Sharma 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB

## Abstract From July 1979 to January 1983, 20 patients with locally advanced head and neck cancer were treated with a combination of chemotherapy and irradiation with or without surgery. A majority of the patients were in the age range of 45 to 54 years. Eighty‐five percent of the patients were ma

Advances in photodynamic therapy for the
Advances in photodynamic therapy for the treatment of head and neck cancers
✍ M. Biel 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract Photodynamic therapy (PDT) is an FDA‐approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death. At the pres

Pretreatment nutritional status and loco
Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy
✍ Mary E. Platek; Mary E. Reid; Gregory E. Wilding; Wainwright Jaggernauth; Nestor 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

Background. This study was carried out to determine if markers of nutritional status predict for locoregional failure following intensity-modulated radiation therapy (IMRT) with concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN). Methods. We performed a ret

Temoporfin-mediated photodynamic therapy
Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study
✍ Ing Bing Tan; Gilles Dolivet; Philippe Ceruse; Vincent Vander Poorten; Gerda Roe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB 👁 1 views

## Abstract ## __Background.__ The aim of this study was to confirm the efficacy of temoporfin (Foscan)‐mediated photodynamic therapy (PDT) in patients with end‐stage head and neck squamous cell carcinoma (HNSCC). ## __Methods.__ Thirty‐nine patients with recurring HNSCC lesions ≤10 mm in depth